Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 20/20 | 0.60 |
| ▸ | CHRM3 | P20309 | 20/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17259572 | 1.00 | ADRB2 (0.60) | ADRB2CHRM3CHRM2 | |
| SCHEMBL17259575 | 1.00 | ADRB2 (0.60) | ADRB2CHRM3CHRM2 | |
| Fluoride SCHEMBL17259934 | 0.99 | ADRB2 (0.59) | ADRB2CHRM3CHRM2 | |
| Fluoride SCHEMBL17259931 | 0.99 | ADRB2 (0.59) | ADRB2CHRM3CHRM2 | |
| Fluoride SCHEMBL17259937 | 0.99 | ADRB2 (0.59) | ADRB2CHRM3CHRM2 | |
| Fluoride SCHEMBL21314066 | 0.99 | ADRB2 (0.59) | ADRB2CHRM3CHRM2 | |
| SCHEMBL17259752 | 0.92 | ADRB2 (0.50) | ADRB2CHRM3CHRM2 | |
| SCHEMBL17259759 | 0.92 | ADRB2 (0.50) | ADRB2CHRM3CHRM2 | |
| SCHEMBL17259755 | 0.92 | ADRB2 (0.50) | ADRB2CHRM3CHRM2 | |
| SCHEMBL17260067 | 0.86 | ADRB2 (0.59) | ADRB2CHRM3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9518050-B2 | Cyclohexyl and quinuclidinyl carbamate derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activity | ALMIRALL, S.A. (ES) | 2016-12-13 | — | — | US | claimed |
| US-20150329535-A1 | NEW CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITY | ALMIRALL, S.A. (ES) | 2015-11-19 | — | — | US | claimed |
| EP-2934594-B1 | CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES . | ALMIRALL SA (ES) | 2019-09-04 | — | — | EP | disclosed |
| US-9518050-B2 | Cyclohexyl and quinuclidinyl carbamate derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activity | ALMIRALL, S.A. (ES) | 2016-12-13 | — | — | US | disclosed |
| US-20150329535-A1 | NEW CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITY | ALMIRALL, S.A. (ES) | 2015-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329535-A1 | NEW CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITY | CHRM3, CHRM2, ADRB2 | ADRB2 3/4885CHRM3 1/4885CHRM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.